PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Earnings season rolls into a high-impact week ahead, with results due from a broad cross-section of the market spanning Big ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald ...